Kristine Slam, MD, FACP, discusses the importance of genetic testing in male patients with breast cancer and why it’s important that all patients with breast cancer advocate for themselves.
Kristine Slam, MD, FACP, Central Ohio Surgical Associates, discusses why treatment for breast cancer in male patients echoes that provided to female patients, the importance of genetic testing in male patients, and why it’s important that all patients with breast cancer advocate for themselves.
"One of the most important things is for patients to understand what their options are," Slam notes. "As a doc, if I don't have a patient asking a lot of questions, I wonder if they're truly listening and comprehending. I expect a lot of questions, I want questions."
Transcript
Can you explain why male breast cancer is so rare and how treatment protocols differ from those for female patients?
Breast cancer is much less common in male patients because in general breast cancer is a function of increasing age, gender, bad luck, and just exogenous estrogen. We make estrogens in our ovaries in our subcutaneous tissue. Obviously, men don't have ovaries, and so that's part of the reason it is much less common. Breast cancer in men, if they end up developing breast cancer, is an immediate indication for genetic testing; there is much more of a hereditary component of a male develops breast cancer. So that's one of the treatment differences is they routinely will undergo genetic testing for BRCA1 and 2 mutations. In general, however, breast cancer in men is still diagnosed at a later stage because they don't believe it can happen. If we do catch it early and they are cognizant of whatnot, we can catch it at an early stage. We have not, as a society, done a lot of studies in breast cancer in male patients so we really do follow the female treatment protocols.
It's still such an uncommon condition. Most of the education, most of the trials, are still based on females. And we just extrapolate the data for male patients. A lot of the trials, when trials need to be developed, need to have a strong number of patients in order for therapies to be validated. And just the n is so small to start with, the outcomes are going to be hard to extrapolate.
What advice would you like to offer patients?
I think one of the most important things for patients is understanding what their options are. I think a lot of patients still do not advocate strongly enough for themselves. Whether it is, “I still have questions about my treatment, please reexplain this” or “I have questions about my financial costs and long-term side effects.” I really encourage patients to not be scared to ask these questions. As a doc, I may not know all the answers. I have to rely on my treatment team, my social workers, my nurse navigators to help get them the answers they need. But I would just strongly encourage patients to advocate for themselves.
Ask away. As a doc, if I don't have a patient asking a lot of questions, I wonder if they're truly listening and comprehending. I expect a lot of questions, I want questions. So that's good.
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More
Decitabine, Venetoclax Combo Boosts Survival in Patients With AML and MDS
May 16th 2024Study findings demonstrate that combining decitabine with venetoclax enhances molecular response rates in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), correlating strongly with improved clinical outcomes and overall survival.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More